In several trials (10, 18, 20), insulin was introduced within the first 6 weeks post-transplant as part of a preventive “β-cell rest” approach aimed at mitigating early postoperative hyperglycemia and reducing the risk of persistent PTDM. The gene discussed is INS; the disease is Hyperglycemia.